MORPHINE SULFATE CR TABLETS 15 mg 100s CII
NDC: 00591-3511-01
*Compare to: MS Contin®, a registered trademark of Purdue Frederick

*Brand names are the trademarks of the products' manufacturers and/or owners.
**Products illustrated may not appear at actual size and/or exact color.

MORPHINE SULFATE CR TABLETS 30 mg 100s CII
NDC: 00591-3512-01
*Compare to: MS Contin®, a registered trademark of Purdue Frederick

*Brand names are the trademarks of the products' manufacturers and/or owners.
**Products illustrated may not appear at actual size and/or exact color.

MORPHINE SULFATE CR TABLETS 60 mg 100s CII
NDC: 00591-3513-01
*Compare to: MS Contin®, a registered trademark of Purdue Frederick

*Brand names are the trademarks of the products' manufacturers and/or owners.
**Products illustrated may not appear at actual size and/or exact color.

MORPHINE SULFATE CR TABLETS 100 mg 100s CII
NDC: 00591-3514-01
*Compare to: MS Contin®, a registered trademark of Purdue Frederick

*Brand names are the trademarks of the products' manufacturers and/or owners.
**Products illustrated may not appear at actual size and/or exact color.

MORPHINE SULFATE CR TABLETS 200 mg 100s CII
NDC: 00591-3515-01
*Compare to: MS Contin®, a registered trademark of Purdue Frederick

*Brand names are the trademarks of the products' manufacturers and/or owners.
**Products illustrated may not appear at actual size and/or exact color.

Morphine Sulfate Controlled-Release Tablets are a controlled-release oral morphine formulation indicated for the relief of moderate to severe pain. It is intended for use in patients who require repeated dosing with potent opioid analgesics over periods of more than a few days.  The Morphine Sulfate Controlled-Release Tablets 100 and 200 mg tablet strengths are high dose, controlled release, oral morphine formulations indicated for the relief of pain in opioid-tolerant patients only.

If clinically advisable, patients receiving Morphine Sulfate Controlled-Release Tablets should be given the following instructions by the physician:

1. Appropriate pain management requires changes in the dose to maintain best pain control. Patients should be advised of the need to contact their physician if pain control is inadequate, but not to change the dose of Morphine Sulfate Controlled-Release Tablets without consulting their physician.

2. Morphine may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating machinery). Patients started on Morphine Sulfate Controlled-Release Tablets or whose dose has been changed should refrain from dangerous activity until it is established that they are not adversely affected.

3. Morphine should not be taken with alcohol or other CNS depressants (sleep aids, tranquilizers) because additive effects including CNS depression may occur. A physician should be consulted if other prescription medications are currently being used or are prescribed for future use.

4. For women of childbearing potential who become or are planning to become pregnant, a physician should be consulted regarding analgesics and other drug use. 

5. Upon completion of therapy, it may be appropriate to taper the morphine dose, rather than abruptly discontinue it.

6. While psychological dependence (“addiction”) to morphine used in the treatment of pain is very rare,

morphine is one of a class of drugs known to be abused and should be handled accordingly.

7. The Morphine Sulfate Controlled-Release 100 and 200 mg Tablet strengths are for use only in opioid-tolerant patients requiring daily morphine equivalent dosages of 200 mg or more. Special care must be taken to avoid accidental ingestion or the use by individuals (including children) other than the patient for whom it was originally prescribed, as such unsupervised use may have severe, even fatal, consequences.